Market Place
Sourcing Support
Tizona Therapeutics Expands Phase 1b Trial for Colorectal Cancer
31 Oct 2024 //
GLOBENEWSWIRE
Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA
26 Jun 2024 //
PR NEWSWIRE
Biond Biologics Doses First Patient With BND-35 In Phase 1 Clinical Trial
24 Jun 2024 //
PR NEWSWIRE
US FDA approves Bristol Myers` colorectal cancer therapy
22 Jun 2024 //
REUTERS
GenFleet`s Fulzerasib Combo Shows Efficacy, Safety In Phase II NSCLC Trial
01 Jun 2024 //
PR NEWSWIRE
ASCO 2024: Rakuten’s photoimmunotherapy & Keytruda combo shows efficacy in HNSCC
28 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Tizona Ttx-080 Phase 1b Data: Crc And Hnscc At Asco 2024
23 May 2024 //
GLOBENEWSWIRE
KRAZATI with Cetuximab Demonstrates Clinically Meaningful Activity
08 Apr 2024 //
BUSINESSWIRE
FDA Accepts sNDA for KRAZATI in Combination with Cetuximab
20 Feb 2024 //
BUSINESSWIRE
Nature Medicine Study Validates Biopsy Assay in Genentech`s Ph 1b of Divarasib
11 Dec 2023 //
GLOBENEWSWIRE
Lupin launches biosimilar cetuximab in pact with Enzene
30 May 2023 //
ECONOMICTIMES
Enzene Biosciences launches Cetuximab, biosimilar of cancer drug Erbitux
30 May 2023 //
EXPRESSPHARMA
SOLVE FSHD invests in Epic Bio for the deP of a novel treatment
18 Apr 2023 //
GLOBENEWSWIRE
GenFleet receives EMA approval for phase Ib/II study of GFH925 with ERBITUX
01 Mar 2023 //
PR NEWSWIRE
GenFleet & Merck Enter into Collaboration to Initiate Study Investigating GFH925
19 Dec 2022 //
PRNEWSWIRE
Jacobio to Collaborate with Merck on Trial of JAB-21822 with Cetuximab
12 Oct 2022 //
PRNEWSWIRE
Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-218822`s PII Study
06 Sep 2022 //
PRNEWSWIRE
ALX starts Phase II trial of colorectal cancer combo therapy
12 Aug 2022 //
CLINICALTRIALSARENA
ALX Oncology Announces First Patient Dosed in Ph2 InG Trial of Evorpacept
11 Aug 2022 //
GLOBENEWSWIRE
Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study
01 Aug 2022 //
BUSINESSWIRE
Erasca, Lilly sign deal to assess colorectal cancer combo therapy
19 Jul 2022 //
CLINICALTRIALSARENA
AVEO & Lilly Sign Trial Collaboration and Supply Agreement for ERBITUX
22 Jun 2022 //
GLOBENEWSWIRE
Biond Biologics Announces First Patients Dosed with BND-22 in PI Trial
23 May 2022 //
PRNEWSWIRE
Erasca Enters Collaboration, Supply Agreement with Eli Lilly for ERAS-007 combo
10 Mar 2022 //
GLOBENEWSWIRE
Jacobio JAB-21822 + Cetuximab Completes First Dose of Colorectal Cancer Patient
23 Feb 2022 //
PRNEWSWIRE
NANOBIOTIX Begins Enrollment in Global Phase III Study of NBTXR3
05 Jan 2022 //
BUSINESSWIRE
Innate Pharma: Monalizumab + Cetuximab & Durvalumab Shows Anti-Tumor Activity
09 Dec 2021 //
BUSINESSWIRE
Jacobio Receives IND Approval for Combo Therapy of KRAS G12C and Cetuximab Inj
05 Dec 2021 //
ASIAONE
Jacobio Receives IND Approval for Comb. Therapy of KRAS G12C & Cetuximab Inj.
05 Dec 2021 //
PRNEWSWIRE
Novitium`s Generic Betaine Receives Approval in the US
23 Nov 2021 //
FDA
AVEO Reports Q3 2021 Financial Results and Provides Business Update
08 Nov 2021 //
BUSINESSWIRE
NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly
23 Oct 2021 //
BUSINESSWIRE
Tizona Begins Phase 1b Expansion Study of TTX-080 in Advanced r/r Malignancies
14 Oct 2021 //
BUSINESSWIRE
FDA expands Lilly`s Erbitux label with Braftovi to treat metastatic CRC
30 Sep 2021 //
PHARMABIZ
Imclone`s Biologic Cetuximab Receives Approval in the US
24 Sep 2021 //
FDA
Adagrasib, Cetuximab Combo Shows Promise in Heavily Pretreated Patients
20 Sep 2021 //
CANCERNETWORK
Mirati Presents +ve Data with Adagrasib in KRAS G12C-Mutated Colorectal Cancer
19 Sep 2021 //
PRNEWSWIRE
Pillar Biosciences` oncoRevealTM Dx lung and colon cancer NGS
05 Aug 2021 //
BUSINESSWIRE
FDA approves new dosing regimen for cetuximab
08 Apr 2021 //
FDA
NICE backs Braftovi for BRAF-positive colorectal cancer
24 Nov 2020 //
PHARMATIMES
Imclone’s Erbitux (Cetuximab) Receives Supplimental Approval In US
11 Nov 2020 //
FDA
Menarini Ricerche Announces C-PRECISE-01, a New Phase Ib/II Trial of MEN1611
02 Jul 2020 //
PIPELINEREVIEW
Junshi Biosciences & Merck Announce Collaboration to Explore COMBINATION
01 Jun 2020 //
GLOBENEWSWIRE
Kitov Announces U.S. FDA Acceptance of INDA to Conduct Ph 1/2 Trial of NT219
22 May 2020 //
GLOBENEWSWIRE
Innate to Present New Efficacy Data For Monalizumab in Combination Cetuximab
14 May 2020 //
GLOBENEWSWIRE
Pierre Fabre receives positive CHMP opinion for BRAFTOVI® (encorafenib) in combo
01 May 2020 //
BUSINESSWIRE
US FDA grants priority review status to Pfizer`s sNDA for Braftov
19 Dec 2019 //
PHARMABIZ
U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI
18 Dec 2019 //
BUSINESS WIRE
EMA validated Pierre Fabre’s application for a Braftov and Mektovi combination
08 Nov 2019 //
PHARMATIMES
Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA®
19 Oct 2019 //
BIOSPACE
Merck gets Chinese approval for Erbitux with Folfox or Folfiri colorectal cancer
28 Sep 2019 //
PHARMABIZ
Innate Pharma and AstraZeneca take monalizumab into phase 3
27 Sep 2019 //
PMLIVE
Pierre Fabre to Present New Data at the ESMO Annual Congress
25 Sep 2019 //
BUSINESSWIRE
Roche, Merck, Novartis and others hike prices on 83 meds starting in July
10 Jul 2019 //
FIERCE PHARMA
Pierre Fabre`s triplet therapy makes strong showing in colorectal cancer
09 Jul 2019 //
PHARMAFILE
Array BioPharma’s Triple-Drug Combo Could be Gamechanger for Colorectal Cancer
08 Jul 2019 //
BIOSPACE
Pierre Fabre and its partner Array BioPharma announce interim analysis results
06 Jul 2019 //
BUSINESSWIRE
Another effort on pancreatic cancer flops, as Boston Biomedical cans Ph 3 test
02 Jul 2019 //
FIERCE BIOTECH
Array played with Pfizer’s eagerness to land a deal on time
01 Jul 2019 //
FIERCE PHARMA
Pfizer, ‘never say never’ with big M&A, inks $11.4B Array cancer deal
18 Jun 2019 //
FIERCE PHARMA
